Nuclear medicine plays an increasingly important role in the management neuroendocrine
neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission …

Context 68 Gallium prostate-specific membrane antigen positron emission tomography (68
Ga-PSMA PET) is an emerging imaging modality for assessment of prostate cancer. Recent …

The recent development of quinoline-based PET tracers that act as fibroblast-activation-
protein inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is …

Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over
conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should …

Ectopic ACTH syndrome (EAS) is rare but is frequently a severe condition because of the
intensity of the hypercortisolism that may be dissociated from the tumoral condition. EAS …

Neuroendocrine neoplasms constitute a diverse group of tumors that derive from the
sensory and secretory neuroendocrine cells and predominantly arise within the pulmonary …

Somatostatin receptors (SSTRs) are variably expressed by a variety of malignancies. Using
radiolabeled somatostatin analogs (SSAs), the presence of SSTRs on tumor cells may be …

Neuroendocrine tumours (NETs) are neoplasms that arise from neuroendocrine cells.
Neuroendocrine cells and their tumours can secrete a wide range of amines and …

Recent studies have focused on the development of total-body PET scanning in a variety of
fields such as clinical oncology, cardiology, personalized medicine, drug development and …

The traditionally promulgated perspectives of neuroendocrine neoplasms (NEN) as rare,
indolent tumours are blunt and have been outdated for the last 2 decades. Clear increments …